OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Gut microbiome, prebiotics, intestinal permeability and diabetes complications	66
Next-generation therapies for adrenocortical carcinoma	61
Menopausal hormone therapy for the management of osteoporosis	58
Gut microbiome and bile acids in obesity-related diseases	54
Epidemiology and mortality of Cushing’s syndrome	51
New perspectives for mitotane treatment of adrenocortical carcinoma	49
Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression	46
Gut microbiome and thyroid autoimmunity	39
Adrenocortical tumorigenesis: Lessons from genetics	38
Genetics of ovarian insufficiency and defects of folliculogenesis	37
Genetic underpinnings of asthenozoospermia	37
TPO antibody positivity and adverse pregnancy outcomes	36
Basics of androgen synthesis and action	36
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	35
Iodine status and supplementation before, during, and after pregnancy	31
Genetics of teratozoospermia: Back to the head	31
Impact of thyroid disease on fertility and assisted conception	31
Hormone therapy regimens for managing the menopause and premature ovarian insufficiency	31
Endocrine-disrupting chemicals and their effects on puberty	30
Adrenocortical hyperplasia: A multifaceted disease	29
Pediatric adrenocortical tumours	29
Diagnosis and differential diagnosis of diabetes insipidus: Update	29
Central diabetes insipidus in children: Diagnosis and management	27
Genetic mutations contributing to non-obstructive azoospermia	27
Management of central diabetes insipidus	26

Endocrine disruptors and the male reproductive system	26
Immune checkpoint inhibitor-related thyroid dysfunction	25
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	25
Phthalates, ovarian function and fertility in adulthood	25
Menopausal hormone therapy and breast cancer risk	25
Acquisition of peak bone mass	24
Endocrine-disrupting chemicals and child health	23
Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide	23
Genetics and epigenetics of autoimmune thyroid diseases: Translational implications	23
Acquired forms of central diabetes insipidus: Mechanisms of disease	23
Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing’s syndrome	22
Endocrine disrupting chemicals and bone	22
Controversies and advances in adrenal venous sampling in the diagnostic workup of primary aldosteronism	22
Thyroid hormone system disrupting chemicals	21
The gut microbiota as a versatile immunomodulator in obesity and associated metabolic disorders	21
Surgery for adrenocortical carcinoma: When and how?	20
Bone marrow adipose tissue: Role in bone remodeling and energy metabolism	20
Cardiovascular complications of mild autonomous cortisol secretion	20
Universal screening for thyroid disease during pregnancy should be performed	20
Gut microbiota and metabolic aspects of cancer cachexia	20
Genetics of 46,XY gonadal dysgenesis	19
Indications for treatment of subclinical hypothyroidism and isolated hypothyroxinaemia in pregnancy	18
The spectrum of low-renin hypertension	18
Gestational diabetes insipidus: Diagnosis and management	18
Management of thyrotoxicosis during pregnancy	18
Osteopathy in mild adrenal Cushing’s syndrome and Cushing disease	18
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	18
Cognitive health after menopause: Does menopausal hormone therapy affect it?	17
Diagnosis and management of premature ovarian insufficiency	17
Quality of life in Cushing’s syndrome	17
Prenatal exposure to phthalate esters and its impact on child development	17
Genetics of cryptorchidism and testicular regression	17
Management of neonates born to mothers with thyroid dysfunction, and points for attention during pregnancy	17
Interpretation of thyroid function tests during pregnancy	16
New types of localization methods for adrenocorticotropic hormone-dependent Cushing’s syndrome	16
Biochemical diagnosis of Cushing’s disease: Screening and confirmatory testing	16
Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases	16
Thyroid dysfunction following pregnancy and implications for breastfeeding	16
Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy	15
Androgens and male sexual function	15
Management of adrenal incidentalomas: Working through uncertainty	15
Marrow adipogenic lineage precursor: A new cellular component of marrow adipose tissue	14
Hormone therapy and cardiovascular disease: Benefits and harms	14
Anaplastic thyroid cancer: An update	14
Primary polydipsia: Update	14
Steroid profiling in the diagnosis of mild and overt Cushing’s syndrome	14
Gut microbiota and their metabolites in cardiovascular disease	14
Pathophysiology of thyroid-associated orbitopathy	14
Paraneoplastic autoimmune hypophysitis: An emerging concept	14
Genetics of anti-Müllerian hormone and its signaling pathway	14